| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
42 |
| Employees |
350 |
| Revenues (TTM) (Millions $) |
23 |
| Net Income (TTM) (Millions $) |
-88 |
| Cash Flow (TTM) (Millions $) |
-98 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Reata Pharmaceuticals Inc. is a biopharmaceutical company that is dedicated to the discovery, development, and commercialization of novel therapeutics for patients with serious or life-threatening diseases. The company was founded in 2002 and is headquartered in Texas, United States.
Reata is focused on developing small molecule drugs that target specific signaling pathways that underlie diseases such as chronic kidney disease, rare genetic diseases, and various forms of cancer. The company's approach is to develop drugs that target specific cellular pathways that are involved in disease progression, including oxidative stress, inflammation, and cellular metabolism.
One of Reata's lead drug candidates is bardoxolone methyl, which is under development for multiple rare and severe conditions. It is a potent activator of a transcription factor called Nrf2, which plays a key role in regulating the body's response to oxidative stress and inflammation. Bardoxolone methyl is currently in clinical trials for chronic kidney disease, pulmonary arterial hypertension, and Alport syndrome.
Another promising drug candidate in Reata's pipeline is omaveloxolone, which is being studied for the treatment of Friedreich's ataxia, a rare genetic disease that affects the nervous system and causes balance problems, difficulty walking, and other symptoms. Omaveloxolone is also being evaluated for the treatment of mitochondrial myopathy, a rare disorder that affects the production of energy within cells.
In addition to its clinical development programs, Reata has a growing portfolio of preclinical programs focused on developing drugs for various types of cancer, including pancreatic cancer and other solid tumors. The company's preclinical pipeline also includes drug candidates for the treatment of rare inherited diseases such as polycystic kidney disease.
Reata has a strong track record of advancing its drug candidates through clinical development and securing FDA approvals. The company has a strategic partnership with Kyowa Kirin Co. Ltd., a global pharmaceutical company, to develop and commercialize bardoxolone methyl in certain territories outside of the United States.
Overall, Reata Pharmaceuticals is a highly innovative biopharmaceutical company that is making significant progress in the development of novel therapeutics for patients with serious and life-threatening diseases. The company's focus on developing drugs that target specific cellular pathways involved in disease progression has the potential to transform the treatment of a range of diseases and improve outcomes for patients.
Company Address: 5320 Legacy Drive Plano 75024 TX
Company Phone Number: 865-2219 Stock Exchange / Ticker: NASDAQ RETA
|
%
2.54%